Pharmacokinetics of an indium-labeled IgG monoclonal antibody over a prolonged period
Identifieur interne : 000100 ( Main/Exploration ); précédent : 000099; suivant : 000101Pharmacokinetics of an indium-labeled IgG monoclonal antibody over a prolonged period
Auteurs : RBID : ISTEX:259_1995_Article_BF00801621.pdfEnglish descriptors
Abstract
This study was directed toward determining the pharmacokinetic fate of an IgG2a monoclonal antibody (MoAb). The 96.5 anti-melanoma MoAb was labeled with indium-111 and indium-114m and administered to BALB/c mice. The mice receiving111In MoAb were sacrificed at 4 and 72 h, while those receiving114mIn 96.5 MoAb (50-day physical half-life) were sacrificed at 4 h and 3, 15, and 30 days. Multiple tissues were counted against a standard of the injectate and the data expressed as percent injected dose per organ and percent total dose excreted in the urine and feces. The 111 In- and114mIn-labeled MoAbs had nearly identical distribution through 72 h. Over the 30-day period 25% of the 114mIn label was excreted in the urine and 50% eliminated in the feces. All of the tissues studied showed a decrease in114mln in the 30-day period. We conclude that the metabolic products of indium-labeled MoAbs, the indium itself, or a combination of both are eliminated from the tissues over a period of several weeks and do not accumulate to a significant extent in any single site.
DOI: 10.1007/BF00801621
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Pharmacokinetics of an indium-labeled IgG monoclonal antibody over a prolonged period</title><author><name>Samuel E. Halpern</name><affiliation wicri:level="1"><mods:affiliation>Veterans Administration Hospital, San Diego, California, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Veterans Administration Hospital, San Diego, California</wicri:regionArea><wicri:noRegion>California</wicri:noRegion></affiliation><affiliation wicri:level="1"><mods:affiliation>University of California, San Diego, California, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of California, San Diego, California</wicri:regionArea><wicri:noRegion>California</wicri:noRegion></affiliation></author><author><name>Richard Bartholomew</name><affiliation wicri:level="1"><mods:affiliation>Hybritech, Inc., San Diego, California, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hybritech, Inc., San Diego, California</wicri:regionArea><wicri:noRegion>California</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1995_Article_BF00801621.pdf</idno><date when="1995">1995</date><idno type="doi">10.1007/BF00801621</idno><idno type="wicri:Area/Main/Corpus">000419</idno><idno type="wicri:Area/Main/Curation">000419</idno><idno type="wicri:Area/Main/Exploration">000100</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Indium-labeled IgG monoclonal antibody</term><term>Mice</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">This study was directed toward determining the pharmacokinetic fate of an IgG2a monoclonal antibody (MoAb). The 96.5 anti-melanoma MoAb was labeled with indium-111 and indium-114m and administered to BALB/c mice. The mice receiving111In MoAb were sacrificed at 4 and 72 h, while those receiving114mIn 96.5 MoAb (50-day physical half-life) were sacrificed at 4 h and 3, 15, and 30 days. Multiple tissues were counted against a standard of the injectate and the data expressed as percent injected dose per organ and percent total dose excreted in the urine and feces. The 111 In- and114mIn-labeled MoAbs had nearly identical distribution through 72 h. Over the 30-day period 25% of the 114mIn label was excreted in the urine and 50% eliminated in the feces. All of the tissues studied showed a decrease in114mln in the 30-day period. We conclude that the metabolic products of indium-labeled MoAbs, the indium itself, or a combination of both are eliminated from the tissues over a period of several weeks and do not accumulate to a significant extent in any single site.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="481db9d0e3190367af9950d3edb94877ec535169"><titleInfo lang="eng"><title>Pharmacokinetics of an indium-labeled IgG monoclonal antibody over a prolonged period</title></titleInfo><name type="personal"><namePart type="given">Samuel E.</namePart><namePart type="family">Halpern</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Veterans Administration Hospital, San Diego, California, USA</affiliation><affiliation>University of California, San Diego, California, USA</affiliation></name><name type="personal"><namePart type="given">Richard</namePart><namePart type="family">Bartholomew</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Hybritech, Inc., San Diego, California, USA</affiliation></name><typeOfResource>text</typeOfResource><genre>Short Communication</genre><genre>Brief Communication</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateCreated encoding="w3cdtf">1995-05-16</dateCreated><dateValid encoding="w3cdtf">2004-11-27</dateValid><copyrightDate encoding="w3cdtf">1995</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">This study was directed toward determining the pharmacokinetic fate of an IgG2a monoclonal antibody (MoAb). The 96.5 anti-melanoma MoAb was labeled with indium-111 and indium-114m and administered to BALB/c mice. The mice receiving111In MoAb were sacrificed at 4 and 72 h, while those receiving114mIn 96.5 MoAb (50-day physical half-life) were sacrificed at 4 h and 3, 15, and 30 days. Multiple tissues were counted against a standard of the injectate and the data expressed as percent injected dose per organ and percent total dose excreted in the urine and feces. The 111 In- and114mIn-labeled MoAbs had nearly identical distribution through 72 h. Over the 30-day period 25% of the 114mIn label was excreted in the urine and 50% eliminated in the feces. All of the tissues studied showed a decrease in114mln in the 30-day period. We conclude that the metabolic products of indium-labeled MoAbs, the indium itself, or a combination of both are eliminated from the tissues over a period of several weeks and do not accumulate to a significant extent in any single site.</abstract><subject lang="eng"><genre>Key words</genre><topic>Indium-labeled IgG monoclonal antibody</topic><topic>Mice</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1995</partNumber><partNumber>Volume: 22</partNumber><partNumber>Number: 11</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1995-11-01</dateIssued><copyrightDate encoding="w3cdtf">1995</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 29</identifier><recordInfo><recordOrigin>Springer-Verlag, 1995</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF00801621</identifier><identifier type="matrixNumber">Art18</identifier><identifier type="local">BF00801621</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>1323</start><end>1325</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1995</recordOrigin><recordIdentifier>259_1995_Article_BF00801621.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000100 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000100 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1995_Article_BF00801621.pdf
|texte= Pharmacokinetics of an indium-labeled IgG monoclonal antibody over a prolonged period
}}
| This area was generated with Dilib version V0.5.81. |  |